FNY Investment Advisers LLC Makes New $132,000 Investment in Hims & Hers Health, Inc. (NYSE:HIMS)

FNY Investment Advisers LLC bought a new position in shares of Hims & Hers Health, Inc. (NYSE:HIMS - Free Report) in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 4,500 shares of the company's stock, valued at approximately $132,000.

Other hedge funds have also modified their holdings of the company. SlateStone Wealth LLC lifted its holdings in Hims & Hers Health by 4.0% in the fourth quarter. SlateStone Wealth LLC now owns 10,640 shares of the company's stock valued at $257,000 after acquiring an additional 413 shares during the period. Blume Capital Management Inc. grew its stake in shares of Hims & Hers Health by 100.0% during the 4th quarter. Blume Capital Management Inc. now owns 1,200 shares of the company's stock worth $29,000 after purchasing an additional 600 shares during the period. Summit Investment Advisors Inc. increased its holdings in shares of Hims & Hers Health by 3.3% in the 4th quarter. Summit Investment Advisors Inc. now owns 19,853 shares of the company's stock valued at $480,000 after purchasing an additional 628 shares in the last quarter. Cim LLC lifted its stake in shares of Hims & Hers Health by 1.0% in the fourth quarter. Cim LLC now owns 71,869 shares of the company's stock valued at $1,738,000 after purchasing an additional 694 shares during the period. Finally, Harbour Investments Inc. lifted its stake in shares of Hims & Hers Health by 18.8% in the fourth quarter. Harbour Investments Inc. now owns 5,269 shares of the company's stock valued at $127,000 after purchasing an additional 833 shares during the period. 63.52% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

HIMS has been the topic of several recent analyst reports. Leerink Partners upped their target price on shares of Hims & Hers Health from $24.00 to $40.00 and gave the stock a "market perform" rating in a research report on Tuesday, February 25th. Needham & Company LLC upped their price target on Hims & Hers Health from $61.00 to $65.00 and gave the stock a "buy" rating in a report on Wednesday, June 4th. Wall Street Zen raised Hims & Hers Health from a "hold" rating to a "buy" rating in a research note on Sunday, June 15th. Piper Sandler reiterated a "neutral" rating and set a $39.00 target price (up from $35.00) on shares of Hims & Hers Health in a research report on Tuesday, May 6th. Finally, TD Cowen cut Hims & Hers Health from a "buy" rating to a "hold" rating and dropped their price target for the company from $44.00 to $30.00 in a research report on Tuesday, April 29th. Two investment analysts have rated the stock with a sell rating, eight have issued a hold rating and four have given a buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of "Hold" and a consensus price target of $38.00.

Insider Activity at Hims & Hers Health

In related news, insider Irene Becklund sold 2,203 shares of the stock in a transaction dated Thursday, April 3rd. The stock was sold at an average price of $28.78, for a total transaction of $63,402.34. Following the transaction, the insider now directly owns 8,007 shares in the company, valued at approximately $230,441.46. This represents a 21.58% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, CEO Andrew Dudum sold 36,460 shares of the firm's stock in a transaction dated Wednesday, April 16th. The stock was sold at an average price of $28.04, for a total value of $1,022,338.40. Following the completion of the sale, the chief executive officer now directly owns 92,103 shares in the company, valued at approximately $2,582,568.12. The trade was a 28.36% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 751,034 shares of company stock valued at $36,486,522. Company insiders own 13.71% of the company's stock.

Hims & Hers Health Trading Up 5.6%

Shares of NYSE HIMS traded up $3.40 during trading on Friday, reaching $64.47. The company had a trading volume of 42,046,852 shares, compared to its average volume of 21,531,031. Hims & Hers Health, Inc. has a twelve month low of $13.47 and a twelve month high of $72.98. The stock has a 50-day moving average price of $47.68 and a two-hundred day moving average price of $38.96. The stock has a market capitalization of $14.43 billion, a PE ratio of 93.44, a price-to-earnings-growth ratio of 2.30 and a beta of 2.09.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last announced its earnings results on Monday, May 5th. The company reported $0.20 earnings per share for the quarter, beating the consensus estimate of $0.12 by $0.08. The firm had revenue of $586.01 million during the quarter, compared to the consensus estimate of $535.21 million. Hims & Hers Health had a net margin of 9.24% and a return on equity of 22.75%. The firm's revenue for the quarter was up 110.7% on a year-over-year basis. During the same quarter in the previous year, the company posted $0.05 EPS. On average, sell-side analysts predict that Hims & Hers Health, Inc. will post 0.29 EPS for the current year.

Hims & Hers Health Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.